When bacteria become resistant to antibiotic treatments, this poses an important threat to health, as infections become very difficult — and sometimes impossible — to treat. But could a new strategy successfully identify the weak point of superbugs?
Antibiotic resistance, defined by bacteria’s lack of susceptibility to drugs that would otherwise be effective against them, has steadily become a significant problem at the global level, with scientists often referring to it as a
Researchers have been working to find solutions for this crisis, suggesting strategies as diverse as using bacteria-killing viruses or compounds derived from cranberries to attack drug-resistant bacteria, or “superbugs.”
Most research into antibiotic resistance has focused on developing new pharmaceutical compounds or completely novel treatments that are not based on known antibiotics.
However, researchers behind a new study from the Emory Antibiotic Resistance Center at the Emory University School of Medicine, in Atlanta, GA, believe that old drugs could be used in new ways to win the race against superbugs.
The study’s authors explain that many bacteria have a type of resistance called “heteroresistance,” which many researchers still struggle to define precisely.
However, by and large, heteroresistance refers to a phenomenon in which, within a larger bacterial population, a subpopulation develops resistance to the antibiotic (or antibiotics) to which other bacteria in the same population respond.
Moreover, since only a few bacteria within a population are drug-resistant, in the case of heteroresistance, doctors may find it hard to detect these instances using regular laboratory tests.
“We can think of heteroresistance as bacteria that are ‘half resistant,'” explains study co-author David Weiss, Ph.D. “When you take the antibiotic away, the resistant cells go back to being just a small part of the group. That’s why they’re hard to see in the tests that hospitals usually use,” he continues.
Weiss and colleagues believe that successfully identifying heteroresistance could help doctors and researchers identify which antibiotic combinations would work best in defeating a mixed population of susceptible and drug-resistant bacteria.
So far, laboratory experiments and research in mouse models — which the investigators present in
In the current study, the research team analyzed 104 bacterial samples (isolates) obtained through the
The researchers used the samples to identify multidrug-resistant bacteria. Among their samples, over 85% of the bacteria showed resistance to at least two different antibiotics.
However, Weiss and colleagues found that in the heteroresistance lay the solution: When they combined the two antibiotics that a bacterial population was resistant to, the mix was more effective in killing the population.
Why? Because within that multidrug-resistant population, different subpopulations were resistant to different antibiotics, which meant that distinct drugs were able to successfully target different bacteria.
The researchers also tested their method on two isolates of pan-resistant Klebsiella pneumoniae bacteria, one of which had been collected from a patient who
The case caused alarm at the time, since that strain of K. pneumoniae, later named Nevada-2016, demonstrated resistance to 26 antibiotics, including the extremely strong drug colistin.
In laboratory experiments, a culture of Nevada-2016 showed heteroresistance to two antibiotics. Yet when the investigators attacked the bacteria with a combination of those antibiotics, the bacteria receded.
The team also performed some tests in mice that they had infected with another heteroresistant — and deadly — strain of K. pneumoniae, AR0040. The researchers identified the drug combination that matched AR0040’s heteroresistance, then treated the mice with it, curing them of the dangerous infection.
Looking more closely at heteroresistance could illuminate more aspects of antibiotic resistance and help identify promising ways to fight it.
The idea of using antibiotic combinations to fight stubborn bacteria is by no means new, but studies such as the current one shed fresh light on why and how this strategy can be effective.
Thus, the authors explain in their paper, “Multiple heteroresistance may explain a significant proportion of antibiotic combinations previously identified as synergistic [working in unison].”
Should heteroresistance to more than one antibiotic become combined within a bacterial strain, however, Weiss notes that the approach in the current study would be ineffective.
Yet, for the time being, the researchers mean to take their experiments further and see how successful their approach can be in the case of other bacteria with heteroresistance.
“We’re saying: Don’t toss those drugs in the trash, they may still have some utility. They just have to be used in combination with others to do so.”
David Weiss, Ph.D.
While, “We can’t tell beforehand what combination will work [since] there isn’t any magic combination,” Weiss says, testing bacterial strains to figure out effective drug mixes “isn’t so much different from testing bacterial strains for resistance to individual antibiotics anyway,” rendering this strategy pragmatically viable.